Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: J Immunol. 2021 Apr 7;206(9):2122–2134. doi: 10.4049/jimmunol.2100018

Figure 5. Antigen-experienced tissue-resident memory CD4 and CD8 T cells are induced by prime-boost RSVNanoVax immunization.

Figure 5.

BALB/c mice were primed with 500 μg of the indicated nanoparticle formulation i.n. on day 0, and boosted with 500 μg i.n. on day 28. No vaccine mice were administered PBS i.n. on both prime and boost days. RSV immune mice received 4.8 × 106 PFU RSV-A2 i.n. at the prime and PBS i.n. at the boost. Lungs and spleens were harvested on day 42 and analyzed by flow cytometry. Frequency of (A) antigen-experienced (CD11ahiCD49d+) CD4 T cells and (B) antigen-experienced (CD11ahiCD8lo) CD8 T cells. Total number of antigen-experienced (C) CD4 T cells and (D) CD8 T cells in the lung. Number of antigen-experienced CD45 intravascular antibody negative (i.v.−) (E) CD103−CD69+ CD4 T cells and (F) CD103+CD69+ CD8 T cells. Statistical significance was determined by (A and B) 2-way ANOVA with a Tukey’s post hoc test or (C-F) one-way ANOVA with a Tukey’s post hoc test. *p<0.05, **p<0.01, ***p<0.001. Data represent mean ± SEM of 2 independent experiments (n=8).